The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | IDH mutations in AML treated with venetoclax
Daniel Pollyea, MD, MS, University of Colorado School of Medicine, Denver, CO, discusses the results of a pooled analysis from two studies (NCT02993523; NCT02203773) of treatment-naïve patients with acute myeloid leukemia (AML) harboring isocitrate dehydrogenase (IDH) mutations. The studies both treated patients with venetoclax (ven) plus azacitidine (aza) and IDH mutation status was assessed using bone marrow aspirates. When IDH 1/2-mutant patient outcomes were pooled, the study showed that complete remission rates were higher in IDH1/2-mutant patients treated with ven+aza compared to those who were classified as IDH not detected. Additionally, overall response rates were higher in those treated with ven+aza compared to aza monotherapy, as was the median duration of response. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
